Treatment strategies for a patient with rheumatoid arthritis and hepatitis C

Bibliography

• Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004;22(2 Suppl 1):1-12
   PubMed Web of Science ®Google Scholar
• Khurana R, Berney SM. Clinical aspects of rheumatoid arthritis. Pathophysiology 2005;12(3):153-65
   PubMedGoogle Scholar
• Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 2002;4(Suppl 3):S265-72
   PubMedGoogle Scholar
• Müller-Ladner U, Pap T, Gay RE, et al. Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol 2005;1(2):102-10
   PubMedGoogle Scholar
• Smith JB, Haynes MK. Rheumatoid arthritis–a molecular understanding. Ann Intern Med 2002;136(12):908-22
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Cervera R, Gershwin ME. Diagnostic criteria in autoimmune diseases. Humana Press 2008. p. 16
   Google Scholar
• Haringman JJ, Ludikhuize J, Tak PP. Chemokines in joint disease: the key to inflammation? Ann Rheum Dis 2004;63:1186-94
   PubMed Web of Science ®Google Scholar
• Takemura S, Braun A, Crowson C, et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001;167(2):1072-80
   PubMed Web of Science ®Google Scholar
• Guedes C, Dumont-Fischer D, Leichter-Nakache S, Boissier MC. Mortality in rheumatoid arthritis. Rev Rheum Engl Ed 1999;66(10):492-8
   PubMedGoogle Scholar
• Möttönen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73
   PubMed Web of Science ®Google Scholar
• Banal F, Dougados M, Combescure C, Gossec L. Sensitivity and specificity of the American College of Rheumatology 1987 criteria for the diagnosis of rheumatoid arthritis according to disease duration: a systematic literature review and meta-analysis. Ann Rheum Dis 2008 In press
   PubMedGoogle Scholar
• Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24
   PubMed Web of Science ®Google Scholar
• Inanc M. Very early ‘Rheumatoid’ arthritis cohorts: limited by selection. Rheumatology (Oxford) 2007;46:185-7
   PubMed Web of Science ®Google Scholar
• Riccio A, Postiglione L, La Dogana P, et al. Anti-cyclic citrullinated peptide antibodies in patients affected by HCV-related arthritis. J Biol Regul Homeost Agents 2008;22(1):57-61
   PubMed Web of Science ®Google Scholar
• Symmons DPM. Classification criteria for rheumatoid arthritis-time to abandon rheumatoid factor? Rheumatology 2007;46:725-6
   PubMed Web of Science ®Google Scholar
• Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis : a systematic literature review. Ann Rheum Dis 2006;65:845-51
   PubMed Web of Science ®Google Scholar
• Young A. Early rheumatoid arthritis. Rheum Dis Clin North Am 2005;31:659-79
   PubMed Web of Science ®Google Scholar
• Syversen SW, Gaarder PI, Goll GL, et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008;67:212-217
   PubMed Web of Science ®Google Scholar
• American College of Rehwumatology subcommittee on rheumatoid arthritis guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46(2):328-46
   PubMed Web of Science ®Google Scholar
• Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52(11):3371-80
   PubMed Web of Science ®Google Scholar
• Svensson B, Boonen A, Albertsson K, et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005;52(11):3360-70
   PubMed Web of Science ®Google Scholar
• Bijlsma JW, Hoes JN, Van Everdingen AA, et al. Are glucocorticoids DMARDs? Ann NY Acad Sci 2006;1069:268-74
   PubMed Web of Science ®Google Scholar
• Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007;(1):CD006356
   Google Scholar
• Aletaha D, Kapral T, Smolen JS. Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. Ann Rheum Dis 2003;62:482-6
   PubMed Web of Science ®Google Scholar
• Choy EH, Smith C, Doré CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford) 2005;44:1414-21
   PubMed Web of Science ®Google Scholar
• Vassilopoulos D, Calabrese LH. Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections. Curr Opin Rheumatol 2007;19(6):619-25
   PubMed Web of Science ®Google Scholar
• Walker AM, Funch D, Dreyer NA, et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 1993;36:329-35
   PubMedGoogle Scholar
• Shergy WJ, Polisson RP, Caldwell DS, et al. Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. Am J Med 1988;85:771-4
   PubMed Web of Science ®Google Scholar
• Mok MY, Ng WL, Yuen MF, et al. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 2000;18:363-8
   PubMed Web of Science ®Google Scholar
• Kujawska A, Clements M, Wise CM, Roberts WN. Hepatitis C and methotrexate. Arthritis Rheum 2003;49(6):843-5
   PubMedGoogle Scholar
• Ferraccioli GF, Gremese E, Tomietto P, et al. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatology (Oxford) 2002;41(8):892-8
   PubMed Web of Science ®Google Scholar
• Ferraccioli GF, Bambara LM, Ferraris M, et al. Effects of cyclosporin on joint damage in rheumatoid arthritis. The Italian Rheumatologists Study Group on Rheumatoid Arthritis. Clin Exp Rheumatol 1997;15(Suppl 17):S83-9
   PubMed Web of Science ®Google Scholar
• Pasero G, Priolo F, Marubini E, et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996;39(6):1006-15
   PubMed Web of Science ®Google Scholar
• Fagiuoli S, Bruni F, Bravi M, et al. Cyclosporin in steroid-resistant autoimmune hepatitis and HCV-related liver diseases. Dig Liver Dis 2007;39(Suppl 3):S379-85
   Google Scholar
• Casanovas Taltavull T. Impact of cyclosporine on the development of immunosuppressive therapy in liver transplantation. Transplant Proc 2004;36(Suppl 2):291S-4S
   Google Scholar
• McCaughan GW. Immunosuppression for HCV following liver transplantation: enough is just enough. Transplantation 2004;78(10):1413-4
   PubMed Web of Science ®Google Scholar
• Ghobrial RM, Colquhoun S, Rosen H, et al. Retransplantation for recurrent hepatitis C following tacrolimus or cyclosporine immunosuppression. Transplant Proc 1998;30(4):1470-1
   PubMed Web of Science ®Google Scholar
• Levy G, Villamil F, Samuel D, et al. LIS2T Study Group. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004;77(11):1632-8
   PubMed Web of Science ®Google Scholar
• Firpi RJ, Zhu H, Morelli G, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006;12(1):51-7
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Sakamoto N, Tanabe Y, et al. Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. Gastroenterology 2005;129:1031-41
   PubMed Web of Science ®Google Scholar
• Rice CM, You S. Treating hepatitis C: can you teach old dogs new tricks? Hepatology 2005;42(6):1455-8
   PubMedGoogle Scholar
• Ishii N, Watashi K, Hishiki T, et al. Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol 2006;80(9):4510-20
   PubMed Web of Science ®Google Scholar
• Henry SD, Metselaar HJ, Lonsdale RC, et al. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology 2006;131(5):1452-62
   PubMed Web of Science ®Google Scholar
• Watashi K, Shimotohno K. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy. Rev Med Virol 2007;17(4):245-52
   PubMed Web of Science ®Google Scholar
• Watashi K, Shimotohno K. Current approaches for developing new anti-HCV agents and analyses of HCV replication using anti-HCV agents. Uirusu 2005;55(1):105-10
   PubMedGoogle Scholar
• Yang F, Robotham JM, Nelson HB, et al. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J Virol 2008;82(11):5269-78
   PubMed Web of Science ®Google Scholar
• Watashi K, Hijikata M, Hosaka M, et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003;38(5):1282-8
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Sakamoto N, Enomoto N, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004;313(1):42-7
   PubMed Web of Science ®Google Scholar
• Robida JM, Nelson HB, Liu Z, Tang H. Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. J Virol 2007;81(11):5829-40
   PubMed Web of Science ®Google Scholar
• Flisiak R, Dumont JM, Crabbé R. Cyclophilin inhibitors in hepatitis C viral infection. Expert Opin Investig Drugs 2007;16(9):1345-54
   PubMed Web of Science ®Google Scholar
• Goto K, Watashi K, Murata T, et al. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. Biochem Biophys Res Commun 2006;343(3):879-84
   PubMed Web of Science ®Google Scholar
• Ma S, Boerner JE, TiongYip C, et al. NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon. Antimicrob Agents Chemother 2006;50(9):2976-82
   PubMed Web of Science ®Google Scholar
• Flisiak R, Horban A, Gallay P, et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 2008;47(3):817-26
   PubMed Web of Science ®Google Scholar
• Paeshuyse J, Kaul A, De Clercq E, et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 2006;43(4):761-70
   PubMed Web of Science ®Google Scholar
• Inoue K, Sekiyama K, Yamada M, et al. Combined interferon alpha 2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 2003;38:567-72
   PubMed Web of Science ®Google Scholar
• Miura H, Itoh Y, Matsumoto Y, et al. Long-term administration of cyclosporin A to HCV-antibody-positive patients with dermatologic diseases. Int J Dermatol 1999;38(4):310-4
   PubMed Web of Science ®Google Scholar
• Rendina M. Chronic HCV hepatitis treatment in patients with autoimmune manifestations with peghilate interferon, ribavirin and CsA. SIMIT Congress. Fiuggi, December 2005
   Google Scholar
• Francavilla G, Vitrani R, Pappalettera A, et al. Patients with lichen planus and HCV infection treated with CsA. G ital malattie infettive 2005;11(Suppl 1):593
   Google Scholar
• Galeazzi M, Bellisai F, Manganelli S, et al. Cyclosporine A for the treatment of autoimmune disorders in HCV infected patients. Autoimmun Rev 2006;5:493-498
   PubMed Web of Science ®Google Scholar
• Galeazzi M, Bellisai F, Giannitti C, et al. Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection. Ann N Y Acad Sci 2007;1110:544-9
   PubMed Web of Science ®Google Scholar
• Galeazzi M, Giannitti C, Manganelli S, et al. Treatment of rheumatic diseases in patients with HCV and HIV infection. Autoimmun Rev 2008;8(2):100-3
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferri C, Galeazzi M, et al. HCV infection: pathogenesis, clinical manifestations and therapy. Clin Exp Rheumatol 2008;26(1 suppl 48):S39-47
   PubMed Web of Science ®Google Scholar
• Galeazzi M, Giannitti C, Manganelli S, et al. Managing co-occurring rheumatoid arthritis and hepatitis C. Eur Musculoskelet Rev (In press)
   Google Scholar
• Calabrese LH, Zein N. Biologic agents and liver toxicity: an added concern or therapeutic opportunity? Nat Clin Pract Rheumatol 2007;3(6):3422-3
   Google Scholar
• Niewold TB, Gibofsky A. Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibitoin for rheumatoid arthritis and hepatitis C. Arthritis Rheum 2006;54:2335-7
   PubMed Web of Science ®Google Scholar
• Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006;21:1366-71
   PubMed Web of Science ®Google Scholar
• Parke FA, Reveille JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004;51:800-4
   PubMed Web of Science ®Google Scholar
• Marotte H, Fontanges E, Bailly F, et al. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford) 2007;46:97-9
   PubMed Web of Science ®Google Scholar
• Oniankitan O, Duvoux C, Challine D, et al. Infliximab therapy for rheumatic diseases in patients with chronic epatitis B or C. J Rheumatol 2004;31:107-9
   PubMed Web of Science ®Google Scholar
• Roux CH, Brocq O, Breuil V, et al. Safety of anti-TNF alpha therapy in rheumatoid arthritis ad spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) 2006;45:1294-7
   PubMed Web of Science ®Google Scholar
• Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumor necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004;63(Suppl 2):ii18-24
   PubMed Web of Science ®Google Scholar
• Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumor necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003;62:1078-82
   PubMed Web of Science ®Google Scholar
• Zein NN. Etanecept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized double blind placebo-controlled study. J Hepatol 2005;42:315-22
   PubMed Web of Science ®Google Scholar
• Khanna M, Shirodkar MA, Gottlieb AB. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatolog Treat 2003;14(4):229-32
   PubMedGoogle Scholar
• Ferri C, Ferraccioli G, Ferrari D, et al. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008;35(10):1944-9
   PubMed Web of Science ®Google Scholar
• Cavazzana I, Ceribelli A, Cattaneo R, Franceschini F. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev 2008;8(2):104-6
   PubMed Web of Science ®Google Scholar
• Tarantino G, Riccio A, Spanò A, et al. HCV infection and chronic arthritis: Does viral replication matter? Hepatol Res 2006;35(4):238-41
   PubMed Web of Science ®Google Scholar
• Xia WL, Shen Y, Zheng SS. Inhibitory effect of cyclosporine A on hepatitis B virus replication in vitro and its possible mechanisms. Hepatobiliary Pancreat Dis Int 2005;4(1):18-22
   PubMedGoogle Scholar
• Xie HY, Xia WL, Zhang CC, et al. Evaluation of hepatitis B virus replication and proteomic analysis of HepG2.2.15 cell line after cyclosporine A treatment. Acta Pharmacol Sin 2007;28(7):975-84
   PubMed Web of Science ®Google Scholar
• McMillan JS, Shaw T, Angus PW, Locarnini SA. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 1995;22(1):36-43
   PubMedGoogle Scholar
• Kallinowski B, Haseroth K, Marinos G, et al. Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 1998;111(2):269-77
   PubMed Web of Science ®Google Scholar
• Nelson DR, Lim HL, Marousis CG, et al. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci 1997;42(12):2487-94
   PubMed Web of Science ®Google Scholar
• Larrea E, Garcia N, Qian C, et al. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996;23(2):210-17
   PubMed Web of Science ®Google Scholar
• Kasahara S, Ando K, Saito K, et al. Lack of tumour necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. J Virol 2003;77:2469-76
   PubMed Web of Science ®Google Scholar
• Herbein G, O'Brien WA. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol. Med 2000;223:241-57
   PubMed Web of Science ®Google Scholar
• Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002;3:333-40
   PubMed Web of Science ®Google Scholar
• Bellisai F, Giannitti C, Donvito A, Galeazzi M. Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection. Clin Rheumatol 2007;26(7):1127-9
   PubMed Web of Science ®Google Scholar